RENOGENYX is developing sequence-based FSHD DNA methylation diagnostics for rapid disease confirmation & characterization.
About epigenetic diagnostics
This website may contain general information relating to various medical conditions and their treatment.
Such information is provided for informational purposes only and is not meant to be a substitute for advice provided by a doctor or other qualified health care professional. Patients should not use the information contained herein for diagnosing a health problem or disease. Patients should always consult with a doctor or other health care professional for medical advice or information about diagnosis and treatment.
CRISPRi Gene Therapy for FSHD, or any other therapeutic program referenced on this website, is not an approved therapeutic product. The information on this website is for illustrative purposes only.
Any suggested treatment protocol, diagnostic process, or any other information related to any medical product is entirely proposed only. No suggestion is made as to the efficacy or safety of any therapeutic product in development. Any approved therapeutic product and/or treatment regimen for any therapy being developed by RENOGENYX may be materially different in scope, nature, and practice than any suggested.